Immutep Ltd (IMMP) is not a strong buy at this time for a beginner investor with a long-term focus. The stock faces significant legal risks due to ongoing class action lawsuits, and its technical indicators do not suggest a strong upward trend. While there is an analyst upgrade with a high price target, the negative catalysts outweigh the positives, and no proprietary trading signals are present to indicate a strong buy opportunity.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 46.574, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.369, with resistance at 0.388 and support at 0.351. Overall, the technical indicators do not suggest a strong buy signal.

An analyst from Maxim upgraded the stock to Buy with a $1.50 price target, which is significantly higher than the current price.
The company is facing multiple class action lawsuits related to alleged securities violations and the failed TACTI-004 trial, creating significant legal and reputational risks. There are no significant hedge fund or insider trading trends to support confidence in the stock.
No financial data available for analysis.
Maxim analyst Jason McCarthy upgraded Immutep to Buy from Hold with a $1.50 price target on 2026-06-17. However, no other recent analyst ratings or price target changes are noted.